Cargando…
Utilization of Psychiatric Team Driven Ketamine Infusions
INTRODUCTION: In 2018 Missouri University Psychiatric Center, an inpatient psychiatric hospital established a ketamine infusion team to treat severely depressed and acutely suicidal clients. Over 80 infusions were delivered over three years, with positive outcomes and minimal side effects. OBJECTIVE...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9566533/ http://dx.doi.org/10.1192/j.eurpsy.2022.1435 |
_version_ | 1784809174144647168 |
---|---|
author | Ithman, M. Sobule, B. Campbell, A. |
author_facet | Ithman, M. Sobule, B. Campbell, A. |
author_sort | Ithman, M. |
collection | PubMed |
description | INTRODUCTION: In 2018 Missouri University Psychiatric Center, an inpatient psychiatric hospital established a ketamine infusion team to treat severely depressed and acutely suicidal clients. Over 80 infusions were delivered over three years, with positive outcomes and minimal side effects. OBJECTIVES: To evaluate outcomes of an inpatient psychiatric intravenous ketamine team to deliver treatment without anesthisia colloabration, which could open the horizon for future intravenous medications in a psychiatric inpatient setting. METHODS: A team consisting of a psychiatrist supported by a psychiatric PA, psychiatric pharmacist, and a mental health nurse devloped a protocol including physical and mental health screening, inclusion/exclusion criteria, dosing, and client monitoring. For data collection, the team monitored vital signs and mental status changes for tolerability and depression screening tools for efficacy. RESULTS: CONCLUSIONS: Overall, ketamine infusions were tolerated well with limited adverse drugs reactions reported or observed and were easily addressed by the team without any serious adverse events. Given the rapid improvement of symptoms and overall tolerability, intravenous ketamine infusions conducted solely by a psychiatric-based team advances our field for further treament modalities. DISCLOSURE: No significant relationships. |
format | Online Article Text |
id | pubmed-9566533 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95665332022-10-17 Utilization of Psychiatric Team Driven Ketamine Infusions Ithman, M. Sobule, B. Campbell, A. Eur Psychiatry Abstract INTRODUCTION: In 2018 Missouri University Psychiatric Center, an inpatient psychiatric hospital established a ketamine infusion team to treat severely depressed and acutely suicidal clients. Over 80 infusions were delivered over three years, with positive outcomes and minimal side effects. OBJECTIVES: To evaluate outcomes of an inpatient psychiatric intravenous ketamine team to deliver treatment without anesthisia colloabration, which could open the horizon for future intravenous medications in a psychiatric inpatient setting. METHODS: A team consisting of a psychiatrist supported by a psychiatric PA, psychiatric pharmacist, and a mental health nurse devloped a protocol including physical and mental health screening, inclusion/exclusion criteria, dosing, and client monitoring. For data collection, the team monitored vital signs and mental status changes for tolerability and depression screening tools for efficacy. RESULTS: CONCLUSIONS: Overall, ketamine infusions were tolerated well with limited adverse drugs reactions reported or observed and were easily addressed by the team without any serious adverse events. Given the rapid improvement of symptoms and overall tolerability, intravenous ketamine infusions conducted solely by a psychiatric-based team advances our field for further treament modalities. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9566533/ http://dx.doi.org/10.1192/j.eurpsy.2022.1435 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Ithman, M. Sobule, B. Campbell, A. Utilization of Psychiatric Team Driven Ketamine Infusions |
title | Utilization of Psychiatric Team Driven Ketamine Infusions |
title_full | Utilization of Psychiatric Team Driven Ketamine Infusions |
title_fullStr | Utilization of Psychiatric Team Driven Ketamine Infusions |
title_full_unstemmed | Utilization of Psychiatric Team Driven Ketamine Infusions |
title_short | Utilization of Psychiatric Team Driven Ketamine Infusions |
title_sort | utilization of psychiatric team driven ketamine infusions |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9566533/ http://dx.doi.org/10.1192/j.eurpsy.2022.1435 |
work_keys_str_mv | AT ithmanm utilizationofpsychiatricteamdrivenketamineinfusions AT sobuleb utilizationofpsychiatricteamdrivenketamineinfusions AT campbella utilizationofpsychiatricteamdrivenketamineinfusions |